Loss of CDKN2A Cooperates with WWTR1(TAZ)–CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
- 4 January 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (13) , 2480-2493
Abstract
Purpose: Epithelioid hemangioendothelioma (EHE) is a vascular sarcoma caused by the WWTR1(TAZ)–CAMTA1 (TC) gene fusion. This fusion gene has been observed in almost all reported EHE cases and functions as a constitutively activated TAZ. Sequencing of human tumors has, however, identified additional secondary mutations in approximately 50% of EHE, most commonly the loss of tumor suppressor CDKN2A. In this study, the effect of loss of CDKN2A in EHE tumorigenesis was evaluated. Experimental Design: Mice bearing a conditional TC allele were paired with a conditional Cdkn2a knockout allele and an endothelial-specific Cre. Histologic characterization and single-cell RNA-seq of the resultant tumors were performed. EHE cell lines were established through ex vivo culture of tumor cells and evaluated for sensitivity to TEAD inhibition and trametinib. Results: Loss of Cdkn2a within EHE was associated with more aggressive disease, as displayed by earlier tumor-related morbidity/mortality and enhanced tumor cell proliferation. As no previous EHE cell lines exist, we attempted, successfully, to expand EHE tumor cells ex vivo and produced the first EHE cell lines. These cell lines are “addicted” to the TC oncoprotein, replicate the EHE transcriptional profile, and generate EHE tumors when injected into immunodeficient mice. Conclusions: CDKN2A loss enhances the tumorigenicity of EHE in vivo and enabled the generation of the first cell lines of this disease. These cell lines replicate key facets of the human disease phenotype. Therefore, these cell lines and allograft tumors generated after implantation serve as robust model systems for therapeutic testing of compounds directed at either EHE or other TAZ-driven cancers.Keywords
All Related Versions
Funding Information
- U.S. Department of War (RA200178)
- Margie and Robert E. Petersen Foundation
- Epithelioid Hemangioendothelioma Foundation
- EHE Rare Cancer Charity UK
- EHE Rare Cancer Charity Australia
- Center for Research and Analysis of Vascular Tumors Foundation
- Velosano
This publication has 52 references indexed in Scilit:
- Cooperative interactions of BRAF V600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapyProceedings of the National Academy of Sciences, 2012
- The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer CellsCell, 2011
- A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sitesGenes, Chromosomes and Cancer, 2011
- A Versatile Viral System for Expression and Depletion of Proteins in Mammalian CellsPLOS ONE, 2009
- DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteriesBlood, 2009
- The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAPCell, 2005
- Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinomaGenes & Development, 2003
- ENDOTHELIAL CELLS IN CULTURE: A MODEL FOR STUDYING VASCULAR FUNCTIONSPharmacological Research, 2000
- Endothelial Cells from Diverse Tissues Exhibit Differences in Growth and MorphologyMicrovascular Research, 1998
- A genetic model for colorectal tumorigenesisCell, 1990